Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1674
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18038101 | ENGINEERED T CELLS FOR EXPRESSION OF CHIMERIC ANITGEN RECEPTORS | Non-Final OA | The Regents of the University of California |
| 18138679 | TARGETING STROMA-CANCER INTERACTIONS IN CANCER | Non-Final OA | The Regents of the University of California |
| 17310279 | TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS | Final Rejection | The Regents of the University of California |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17431276 | USE OF A STIMULATING AGENT TO ASSAY IMMUNE CELL POTENCY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18177023 | TRANSFORMED NATURAL KILLER CELL | Non-Final OA | Purdue Research Foundation |
| 18317797 | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18264604 | CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18284209 | HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17290128 | PEPTIDES, COMPOSITIONS AND VACCINES FOR TREATMENT OF MICROSATELLITE INSTABLITY HYPERMUTATED TUMORS AND METHODS OF USE THEREOF | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | Non-Final OA | City of Hope |
| 18201620 | USE OF ANTI-IL-27 ANTIBODIES | Non-Final OA | MSD INTERNATIONAL GMBH |
| 17264522 | IMMUNE MODIFYING PARTICLES FOR THE TREATMENT OF CANCER | Final Rejection | onCour Pharma, Inc. |
| 17290439 | HER2 S310F SPECIFIC ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18179201 | MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | Final Rejection | CRISPR THERAPEUTICS AG |
| 16978953 | ANTI-PD-1 VACCINE COMPOSITION | Non-Final OA | CONSERVATOIRE NATIONAL DES ARTS ET METIERS |
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18248979 | ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Five Prime Therapeutics, Inc. |
| 17598650 | ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY | Final Rejection | CytoDyn Inc. |
| 18551146 | HYBRID MOLECULE COMPRISING A FIBRIN-DERIVED CITRULLINATED PEPTIDE AND AN ANTIBODY OR ANTIBODY FRAGMENT WHICH BINDS TO CD38 AND/OR CD138, AND USES THEREOF | Non-Final OA | ARTHRITIS RECHERCHE & DEVELOPPEMENT |
| 18218535 | Sialylated Glycoproteins | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | Final Rejection | BIONTECH US INC. |
| 18266435 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS AND COMPOSITIONS THEREOF | Non-Final OA | GARUDA THERAPEUTICS, INC. |
| 18266340 | PRAME BINDING MOLECULE | Non-Final OA | MIE UNIVERSITY |
| 18249879 | ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF | Final Rejection | Janux Therapeutics, Inc. |
| 18041770 | RECOMBINANT IMMUNOTOXIN COMPRISING A RIBOTOXIN OR RNASE | Final Rejection | ATB Therapeutics |
| 17258529 | Cyclic Single-Chain Antibody | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY |
| 17792993 | A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL | Non-Final OA | Acepodia Biotechnologies Ltd. |
| 17680468 | MODULAR ASSEMBLY RECEPTORS AND USES THEREOF | Final Rejection | 12343096 CANADA INC. |
| 17423599 | FORMULATIONS OF ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | Final Rejection | Compass Therapeutics LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy